Volume 1, No. 6
October 2015
© 2015 MorNuCo, Inc.
All rights reserved.

MorNuCo Inc., Purdue Research Park, 1201 Cumberland Ave, W Lafayette, IN 47906 To subscribe, e-mail: processing@oncoblotlabs.com

Incidence of ONCOblot Detection of ENOX2 in Young Adults

D. James Morré, PhD and David J. Taggart, PhD

MorNuCo, Inc. continues its monthly report for participating physicians and health professionals in order to answer common questions relating to the ONCOblot® Tissue of Origin (Cancer) Test.

As a further assessment of the false positive error rate for the ONCOblot[®] Tissue of Origin Cancer Test, the incidence of ENOX2 presence in the serum of young adults, 20 to 39 years of age, was evaluated.

Methods

Sera of 50 male and 50 female volunteers, without clinical evidence of cancer, between 20 and 39 years of age were analyzed for the presence of ENOX2 proteins by the ONCOblot® Tissue of Origin Cancer Test. Sera were collected by venipuncture, stored and analyzed using IRB approved protocols.

Results

In the age group 20-29 years, none of the 25 females and only one (colorectal) of the 25 males exhibited ENOX2 proteins indicative of cancer presence. Similarly, in the age group 30 to 39 years, one (blood cell) of the 25 females and one (prostate) of the 25 males exhibited ENOX2 proteins. Therefore, the overall incidence of ENOX2 presence within all 100 serum samples analyzed was 3%.

Discussion

The predicted incidence of newly diagnosed cancers within a population of men and women between 20 to 39 years old is approximately 2%, as predicted by NCI's SEER Cancer Statistics Review (1). The difference between the present findings of a 3% incidence of ENOX2 proteins within

100 subjects from this age range and the predicted incidence of newly diagnosed cancers within this population (3% - 2% = 1%) is consistent with the previously estimated false positive rate of <1% for the ONCOblot[®] Tissue of Origin Cancer Test (2).

Conclusion

The sera from 100 subjects (50 male and 50 female) between the ages of 20 and 39 years were analyzed for ENOX2 presence provide findings consistent with a previous estimate of a false positive incidence of less than or equal to 1% for the ONCOblot[®] Tissue of Origin Cancer Test.

References

- 1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feurer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
- 2. Morré DJ, Gilmartin D. Estimation of the Accuracy of the ONCOblot[®] Tissue of Origin Cancer Test. ONCOblot[®] Reports 1 (No. 1), May 2015.